Aytu BioPharma, Inc (AYTU) stock
AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3070% below fair value
$2.66+0.84 (+46.15%)
Close on Nov 17, 2026Market cap $28.91MP/E –Yield –
Aytu BioPharma total assets
Total assets on the balance sheet at the end of each period.
Aytu BioPharma's total assets was $105.01M at Jun 30, 2026. For fiscal 2026 it was $105.01M, down 15.4% from the year before. Over ten years it grew 15.7% a year on average. The highest annual figure on record is $265.67M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $105.01M | -15.4% |
| FY2025 | Jun 30, 2025 | $124.18M | +5.2% |
| FY2024 | Jun 30, 2024 | $118.10M | -13.5% |
| FY2023 | Jun 30, 2023 | $136.46M | -0.8% |
| FY2022 | Jun 30, 2022 | $137.62M | -48.2% |
| FY2021 | Jun 30, 2021 | $265.67M | +73.3% |
| FY2020 | Jun 30, 2020 | $153.29M | +341.5% |
| FY2019 | Jun 30, 2019 | $34.72M | +64.9% |
| FY2018 | Jun 30, 2018 | $21.06M | +40.4% |
| FY2017 | Jun 30, 2017 | $15.00M | -38.4% |
| FY2016 | Jun 30, 2016 | $24.34M | +33.9% |
| FY2015 | Jun 30, 2015 | $18.19M | +187979.2% |
| FY2013 | Aug 31, 2013 | $9.67K | -23.5% |
| FY2012 | Aug 31, 2012 | $12.65K | -44.6% |
| FY2011 | Aug 31, 2011 | $22.84K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $105.01M | -15.4% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $111.69M | -10.1% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $122.00M | +5.0% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $124.99M | +7.9% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $124.18M | +5.2% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $124.20M | -3.6% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $116.23M | -11.4% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $115.83M | -12.8% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $118.10M | -13.5% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $128.86M | -12.5% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $131.25M | -7.2% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $132.89M | -11.4% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $136.46M | -0.8% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $147.22M | -12.8% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $141.44M | -36.8% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $150.00M | -34.1% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $137.62M | -48.2% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $168.83M | -37.8% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $223.82M | +34.2% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $227.73M | +61.2% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $265.67M | +73.3% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $271.56M | +70.8% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $166.74M | +123.9% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $141.27M | +355.4% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $153.29M | +341.5% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $158.95M | +314.6% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $74.48M | +75.7% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $31.02M | +72.5% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $34.72M | +64.9% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $38.34M | +64.0% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $42.40M | +124.8% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $17.98M | -15.3% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $21.06M | +40.4% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $23.37M | +46.9% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $18.86M | -12.3% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $21.25M | +41.6% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $15.00M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $15.92M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $21.51M | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $15.00M | – |
See a number that looks wrong?